Mumbai: With a near-40% price cut, Novo Nordisk has finally broken the cost barrier for Wegovy, which had struggled to gain traction in India’s market for weight-loss drugs. The discount, announced last month, is already showing results in increased adoption as Wegovy’s sales volume surged 70% in November within about 20 days of the price…
Indian generic drugmakers are recalibrating their pricing strategy after Danish drugmaker Novo Nordisk decided to cut by nearly 40% prices of its weight-loss injectable semaglutide, sold under brand name Wegovy. Companies preparing for the first wave of semaglutide launches are now said to be working with a โน3,000-5,000 band as against a โน7,000-8,000 a month…
Novo Nordiskโs strategy in India is shaped not by competitive pressures but by a long-term commitment to the country, Vikrant Shrotriya, the India head of the Danish drugmaker, told ET. โWe are not in a numbers game. What is more satisfying is when you see people benefiting from the medicineโฆ And when we do this…
Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters. Wegovy’s highest dose of 2.4 mg will now cost 16,400 rupees ($186.59), compared with its earlier price of 24,389.06 rupees, the document sent by Novo to drug…